Monitor the poster presentation on July 12 for any data readouts on immune response or viral neutralization. No immediate trading catalyst; the stock may see limited movement unless the data reveals a clear differentiation from existing CMV vaccine approaches.
Price Chart
Executive Summary
Evaxion announced a poster presentation of preclinical data for its CMV vaccine candidate EVX-V1 at the International Herpesvirus Workshop on July 12, 2026. The data will guide final antigen selection for the candidate, which combines AI-discovered and AI-optimized antigens. This is a routine pipeline update with no financial or clinical data disclosed.
Key Facts
- Evaxion will present preclinical data for CMV vaccine candidate EVX-V1 at IHW 2026 in Montreal on July 12, 2026.
- EVX-V1 is a multi-component vaccine combining novel AI-discovered antigens with AI-optimized versions of established CMV antigens.
- No CMV vaccine has been approved to date; the CMV treatment market was valued at $474.6M in 2023 with 6.6% CAGR forecast.
- The presentation will guide final antigen selection for a broadly protective CMV vaccine candidate.
Financial Impact
No financial figures disclosed; preclinical data presentation has no direct revenue or earnings impact.
Risk Factors
- Preclinical data may not translate to clinical efficacy or regulatory success.
- Evaxion is a clinical-stage company with no approved products and likely needs additional capital to fund development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004414 |
| Document: f6k_070126.htm | 0001171843-26-004414 |
| Document: 0001171843-26-004414-index-headers.html | 0001171843-26-004414 |
| Document: 0001171843-26-004414-index.html | 0001171843-26-004414 |
| Document: 0001171843-26-004414.txt | 0001171843-26-004414 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access